Cytosorbents vs KORU Medical Systems
CTSO and KRMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTSO and KRMD compare
Cytosorbents is the larger company, worth 2.0 times as much as KORU Medical Systems ($337M against $170M).
KORU Medical Systems grew revenue faster over the last twelve months (18.4% versus 3.1% for Cytosorbents).
KORU Medical Systems keeps more of each dollar of sales as profit, with a net margin of −1.8% compared with −48.9% at Cytosorbents.
KORU Medical Systems scores higher on the StockData Score (13 against 2 for Cytosorbents), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTSO | KRMD |
|---|---|---|
| Size and price | ||
| Market cap | $337M | $170M |
| Share price | $5.37 | $3.69 |
| Change, 1 year | −61.5% | −1.1% |
| Change, 5 years | −94.9% | 8.5% |
| Beta (5Y) | 0.96 | 1.00 |
| Employees | 129 | 73 |
| StockData Score | ||
| Total score | 2 | 13 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.1× | 3.7× (better) |
| P/B | – | 8.8× |
| EV/EBITDA | – | 820× |
| FCF yield | −2.8% | −0.23% (better) |
| Growth | ||
| Revenue growth (TTM) | 3.1% | 18.4% (better) |
| Revenue growth, 5Y average | −2.0% | 11.2% (better) |
| Profitability | ||
| Gross margin | 71.6% (better) | 63.6% |
| Operating margin | −34.7% | −1.3% (better) |
| Net margin | −48.9% | −1.8% (better) |
| FCF margin | −25.0% | −0.84% (better) |
| Return on equity | −336% | −4.6% (better) |
| Return on invested capital | −73.4% | −4.7% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.66 | 2.97 (better) |
| Altman Z-score | −7.04 | 11.41 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.3% | 44.5% |
| Held by insiders | 2.5% | 17.6% |
| Insider net buying, 12 months | $269K | $1.6M (better) |
| Short interest, % of float | 0.22% | 2.3% |
Go deeper
- CTSO stock overview
- CTSO income statement
- CTSO valuation and score
- KRMD stock overview
- KRMD income statement
- KRMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.